Dona (glucosamine sulfate) ampoules 2 ml. №6 + solvent 1 ml

Description

DONA COMPOSITION
active substance: 2 ml of solution (ampoule A) contains crystalline glucosamine sulfate 502.5 mg equivalent glucosamine sulfate 400 mg and sodium chloride 102.5 mg

excipients: lidocaine hydrochloride, water for injection

solvent (ampoule B) contains

excipients: diethanolamine, water for injection.

DONA DOSAGE FORM
Injection.

MAIN PHYSICAL AND CHEMICAL PROPERTIES:
ampoule A made of brown transparent glass contains a colorless or light brown transparent liquid without suspended particles

ampoule B (solvent) from a colorless transparent glass contains a colorless transparent liquid without suspended particles

ampoule A + B (for injection) is a light brown transparent solution that does not contain suspended particles.

DONA PHARMACOLOGICAL GROUP
Non-steroidal anti-inflammatory drugs.

ATX code M01A X05.

PHARMACOLOGICAL PROPERTIES
Pharmacological.

The active ingredient, glucosamine sulfate, is a salt of the amino monosaccharide glucosamine, which is present in the human body under physiological conditions and is used together with sulfates for the biosynthesis of hyaluronic acid in the synovial fluid and glycosaminoglycans of the main substance of the articular cartilage.

Thus, the mechanism of action of glucosamine sulfate is to stimulate the synthesis of glycosaminoglycans and, accordingly, articular proteoglycans. In addition, glucosamine has an anti-inflammatory effect and inhibits the process of destruction of articular cartilage mainly due to possible manifestations of its own metabolic properties, the ability to suppress the activity of interleukin 1 (IL-1), which, on the one hand, affects the symptoms of osteoarthritis, and on the other hand, potentially delays structural joint damage, as evidenced by data from long-term clinical studies.

According to initial in vitro and in vivo studies, exogenous administration of glucosamine sulfate stimulates proteoglycan biosynthesis, which is insufficient in osteoarthritis, promotes the fixation of sulfur ions during glycosaminoglycan synthesis, and improves trophic articular cartilage.

Subsequent studies have shown that glucosamine sulfate inhibits the synthesis of tissue-damaging substances such as superoxide radicals, as well as the activity of lysosomal enzymes in addition to enzymes capable of damaging articular cartilage tissue, such as collagenases and phospholipases A2. This action causes a moderate anti-inflammatory effect, which is observed in animal models in vivo, including in some cases with experimental osteoarthritis, even without inhibition of cyclooxygenase, in contrast to non-steroidal anti-inflammatory drugs (NSAIDs).

INDICATIONS
Treatment of osteoarthritis symptoms: pain and functional limitation.

CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients, a tendency to bleeding.

The injectable form of the drug includes the auxiliary substance lidocaine, which has the following contraindications: cardiogenic shock, severe arterial hypotension, severe forms of chronic heart failure, reduced left ventricular function, block II-III degree, severe bradycardia, blood clotting disorders, Wolff-Parkinson’s syndrome -White, Adams-Stokes syndrome, a history of seizures caused by lidocaine, sick sinus syndrome, severe liver dysfunction, hypovolemia, myasthenia gravis, infection at the injection site, hypersensitivity to other amide-type anesthetics (since there is an increased risk of cross-reactions) hypersensitivity).